Kalaris Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the period ended September 30, 2026.

Key Highlights

  • Share count: As of November 3, 2026, the registrant had 23,804,981 shares of common stock, $0.0001 par value per share, outstanding.
  • Listing: Common stock trades on the Nasdaq Global Market under the symbol KLRS (NASDAQ:KLRS).
  • No product revenue: According to the filing, the company has never generated revenue from product sales.
  • Ongoing losses: The company disclosed it has incurred significant losses since inception and expects to continue incurring significant expenses and operating losses for the foreseeable future.
  • Sole pipeline candidate: The company disclosed it is heavily dependent on the success of its product candidate TH103.
  • Filer classification: The registrant is identified as a non-accelerated filer and a smaller reporting company.
  • Corporate history: The company is formerly known as AlloVir, Inc., following a completed merger with Legacy Kalaris (formerly Kalaris Therapeutics, Inc.).

Kalaris Therapeutics and Its TH103 Development Stage Operations

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company incorporated in Delaware, with principal executive offices located in Berkeley Heights, New Jersey. The company was formerly known as AlloVir, Inc. and assumed its current identity following the completion of a merger with Kalaris Tx, Inc., formerly called Kalaris Therapeutics, Inc. The filing uses the term "Legacy Kalaris" to refer to the pre-merger entity.

According to the filing, the company's development efforts are centered on TH103, its sole disclosed product candidate. The company disclosed that it relies on a commercial-scale drug substance manufacturer to supply TH103 drug substance meeting quality standards and applicable regulatory requirements for clinical development. The filing also noted risks tied to the ability to obtain, maintain, and protect intellectual property rights related to TH103, as well as uncertainty regarding clinical results and regulatory approval timelines.

The company disclosed that it has never generated revenue from product sales and that it expects to continue incurring significant expenses and operating losses for the foreseeable future, with no assurance it will ever achieve or maintain profitability. These characterizations are the company's own, made in the context of forward-looking statements that the filing states are subject to risks, uncertainties, and cautionary language contained within the report. The filing was submitted with Commission File Number 001-39409.

What Was Disclosed

Kalaris Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, reporting 23,804,981 shares of common stock outstanding as of November 3, 2026, continued operating losses, no product revenue, and ongoing clinical development of TH103 on the Nasdaq Global Market under NASDAQ:KLRS.